Clinical outcomes in cohorts with conservative or surgery treatment, according to NT-proBNP tertiles
| 1-Year death | 30-Day death | |||||
| No. of events/total patients (%)* | HR (95% CI) | P value | No. of events/total patients (%) | OR (95% CI) | P value | |
| Conservative† | ||||||
| T1 (≤155.0) | 44/62 (71.0) | Reference | – | 43/62 (69.4) | Reference | – |
| T2 (155.0–671.4) | 77/106 (72.6) | 1.00 (0.69 to 1.45) | 0.99 | 75/106 (70.8) | 1.07 (0.54 to 2.12) | 0.85 |
| T3 (>671.4) | 105/137 (76.6) | 1.05 (0.74 to 1.49) | 0.79 | 98/137 (71.5) | 1.10 (0.58 to 2.14) | 0.75 |
| Surgery† | ||||||
| T1 (≤155.0) | 6/214 (2.8) | Reference | – | 4/214 (1.9) | Reference | – |
| T2 (155.0–671.4) | 13/171 (7.6) | 2.79 (1.06 to 7.33) | 0.04 | 8/171 (4.7) | 2.58 (0.76 to 8.70) | 0.13 |
| T3 (>671.4) | 11/139 (7.9) | 2.89 (1.07 to 7.81) | 0.04 | 5/139 (3.6) | 1.96 (0.52 to 7.43) | 0.32 |
*Values are Kaplan-Meier estimated rates.
†P for interaction for the risk of 1-year death: NT-proBNP tertiles and treatment strategy (conservative or surgery) = 0.04; P for interaction for the risk of 30-day death: NT-proBNP levels (low or high) and treatment strategy (conservative or surgery) = 0.18.
NT-proBNP, N-terminal pro-brain natriuretic peptide.